
Thalassemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Thalassemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Drugs In Development, 2022, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 15, 8, 1, 2, 22 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase 0, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.
Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Drugs In Development, 2022, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 15, 8, 1, 2, 22 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase 0, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.
Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
155 Pages
- Introduction
- Global Markets Direct Report Coverage
- Thalassemia – Overview
- Thalassemia – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Thalassemia – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Thalassemia – Companies Involved in Therapeutics Development
- Abfero Pharmaceuticals Inc
- Acceleron Pharma Inc
- Agios Pharmaceuticals Inc
- Aruvant Sciences Inc
- ASC Therapeutics Inc
- Ascentage Pharma Group Inc
- Beam Therapeutics Inc
- Bellicum Pharmaceuticals Inc
- BGI Genomics Co Ltd
- Biomac Lifesciences Pvt Ltd
- bluebird bio Inc
- Cell Source Inc
- Cetya Therapeutics Inc
- Complexa Inc
- CRISPR Therapeutics AG
- CSL Ltd
- Disc Medicine Inc
- DisperSol Technologies LLC
- EdiGene Inc
- Editas Medicine Inc
- Epidestiny Inc
- Forma Therapeutics Inc
- Fulcrum Therapeutics Inc
- Gamida Cell Ltd
- Garuda Therapeutics Inc
- Gilead Sciences Inc
- Graphite Bio Inc
- Hangzhou Zede Pharmaceutical Technology Co Ltd
- Imago BioSciences Inc
- ImmuneCyte Inc
- Invenux LLC
- Ionis Pharmaceuticals Inc
- Jasper Therapeutics Inc
- Jazz Pharmaceuticals Plc
- Kanglin Biotech Hangzhou Co Ltd
- Kymab Ltd
- Mabwell Shanghai Bioscience Co Ltd
- Merganser Biotech Inc
- Monte Rosa Therapeutics Inc
- Nanomedic Inc
- Orchard Therapeutics Plc
- Phoenicia Biosciences Inc
- Rare Partners Srl
- Regenacy Pharmaceuticals LLC
- San Rocco Therapeutics LLC
- Sana Biotechnology Inc
- Sanquin Plasma Products BV
- Shanghai Bendao Gene Technology Co Ltd
- Shanghai Bioray Laboratory Inc
- Shanghai Pharmaceuticals Holding Co Ltd
- Silence Therapeutics Plc
- Suzhou GenAssist Therapeutics Co Ltd
- Syros Pharmaceuticals Inc
- TransThera Sciences (Nanjing) Inc
- Vera Therapeutics Inc
- Vertex Pharmaceuticals Inc
- Vifor Pharma Ltd
- Thalassemia – Drug Profiles
- (decitabine + tetrahydrouridine) – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- 9MW-3011 – Drug Profile
- Product Description
- Mechanism Of Action
- ACY-957 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ambrisentan – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APG-5918 – Drug Profile
- Product Description
- Mechanism Of Action
- ARU-1801 – Drug Profile
- Product Description
- Mechanism Of Action
- ASC-520 – Drug Profile
- Product Description
- Mechanism Of Action
- BCL11A – Drug Profile
- Product Description
- Mechanism Of Action
- BD-211 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BEAM-101 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- benserazide hydrochloride – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- betibeglogene autotemcel – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BRL-101 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BRL-102 – Drug Profile
- Product Description
- Mechanism Of Action
- BRL-105 – Drug Profile
- Product Description
- Mechanism Of Action
- BYC-103 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cell Therapies for Hematological Disorders and Hematological Tumor – Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Hematological Disorders – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CN-128 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CSL-200 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CT-101 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CTX-001 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CXA-10 – Drug Profile
- Product Description
- Mechanism Of Action
- deferasirox – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- defibrotide sodium – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EDIT-301 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ET-01 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- etavopivat – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- FTX-6058 – Drug Profile
- Product Description
- Mechanism Of Action
- GEN-7010 – Drug Profile
- Product Description
- Mechanism Of Action
- Gene Modified Cell Therapies for Beta Thalassemia and Sickle Cell Disease – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy for Sickle Cell Disease and Beta Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate Beta Globin for Beta Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate HBB for Beta Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate IGF2BP1 for Sickle Cell Disease and Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- Gene-Modified Cell Therapies for Autoimmune Diseases, Sickle Cell Disease and Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GPH-102 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HbF Induction – Drug Profile
- Product Description
- Mechanism Of Action
- IMC-2032 – Drug Profile
- Product Description
- Mechanism Of Action
- KLTH-02 – Drug Profile
- Product Description
- Mechanism Of Action
- KY-1066 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- luspatercept – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- M-009 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mitapivat sulfate – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibodies to Inhibit Erythroferrone for Beta Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- Oligonucleotides to Activate HBB for Beta Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- omidubicel – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OTL-300 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Protein for Beta Thalassaemia and Congenital Hypotransferrinaemia – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rivogenlecleucel – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RM-001 – Drug Profile
- Product Description
- Mechanism Of Action
- sapablursen sodium – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SCD-101 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SG-418 – Drug Profile
- Product Description
- Mechanism Of Action
- sirolimus – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SLN-124 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule for Beta Thalassemia – Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit Matriptase-2 for Hematologic Disorders – Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit LSD1 for Thalassemia and Sickle Cell Disease – Drug Profile
- Product Description
- Mechanism Of Action
- sotatercept – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SP-420 – Drug Profile
- Product Description
- Mechanism Of Action
- SRD-6214 – Drug Profile
- Product Description
- Mechanism Of Action
- Thalagen – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ThalaGenX – Drug Profile
- Product Description
- Mechanism Of Action
- TT-00961 – Drug Profile
- Product Description
- Mechanism Of Action
- vamifeport hydrochloride – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Thalassemia – Dormant Projects
- Thalassemia – Discontinued Products
- Thalassemia – Product Development Milestones
- Featured News & Press Releases
- Apr 12, 2022: San Rocco Therapeutics pushes clinical trial for a curative treatment for beta-thalassemia and sickle cell disease
- Mar 25, 2022: Bristol Myers Squibb announces new Prescription Drug User Fee Act goal date for Reblozyl (luspatercept-aamt) supplemental biologics license application
- Jan 25, 2022: Sickle cell disease and transfusion-dependent beta thalassemia: promising results of gene therapy treatment
- Jan 18, 2022: bluebird provides update on FDA review timelines for Betibeglogene Autotemcel (beti-cel) for beta-thalassemia
- Dec 20, 2021: Editas Medicine announces FDA clearance of investigational new drug (IND) application for EDIT-301 for the treatment of transfusion-dependent beta thalassemia
- Dec 14, 2021: Imara presents preclinical data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
- Dec 13, 2021: Agios Presents mitapivat data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis in non-transfusion-dependent a- and ß-thalassemia at 63rd ASH Annual Meeting and Exposition
- Dec 12, 2021: New data from SLN124 healthy volunteer study reinforce broad therapeutic potential in hematological diseases
- Dec 11, 2021: New data at ASH21, published in NEJM further demonstrate beti-cel as a potentially curative one-time gene therapy for ß-thalassemia patients who require regular transfusions through achievement of durable TI and normal or near-normal adult Hb levels
- Dec 06, 2021: Fulcrum Therapeutics announces additional HBG mRNA induction from higher dose cohorts in phase 1 healthy adult volunteer trial of FTX-6058 for sickle cell disease and new preclinical mechanism data
- Dec 03, 2021: U.S. Food and Drug Administration accepts for priority review supplemental biologics license application for Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent (NTD) beta thalassemia
- Nov 22, 2021: bluebird bio announces FDA priority review of biologics license application for beti-cel gene therapy for patients with ß-thalassemia who require regular red blood cell transfusions
- Nov 04, 2021: Imara to present preclinical data at the American Society of Hematology (ASH) Annual Meeting 2021
- Nov 04, 2021: EdiGene to present latest research on a novel surface marker and migration of hematopoietic stem cell (HSC) that could enhance HSC gene therapy and HSC transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
- Nov 04, 2021: Editas Medicine to present data demonstrating progress towards transformative gene editing medicines for the treatment of hemoglobinopathies and cancer at the ASH Annual Meeting and Exposition
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Thalassemia, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Products under Development by Universities/Institutes, 2022
- Table 11: Number of Products by Stage and Target, 2022
- Table 12: Number of Products by Stage and Mechanism of Action, 2022
- Table 13: Number of Products by Stage and Route of Administration, 2022
- Table 14: Number of Products by Stage and Molecule Type, 2022
- Table 15: Thalassemia – Pipeline by Abfero Pharmaceuticals Inc, 2022
- Table 16: Thalassemia – Pipeline by Acceleron Pharma Inc, 2022
- Table 17: Thalassemia – Pipeline by Agios Pharmaceuticals Inc, 2022
- Table 18: Thalassemia – Pipeline by Aruvant Sciences Inc, 2022
- Table 19: Thalassemia – Pipeline by ASC Therapeutics Inc, 2022
- Table 20: Thalassemia – Pipeline by Ascentage Pharma Group Inc, 2022
- Table 21: Thalassemia – Pipeline by Beam Therapeutics Inc, 2022
- Table 22: Thalassemia – Pipeline by Bellicum Pharmaceuticals Inc, 2022
- Table 23: Thalassemia – Pipeline by BGI Genomics Co Ltd, 2022
- Table 24: Thalassemia – Pipeline by Biomac Lifesciences Pvt Ltd, 2022
- Table 25: Thalassemia – Pipeline by bluebird bio Inc, 2022
- Table 26: Thalassemia – Pipeline by Cell Source Inc, 2022
- Table 27: Thalassemia – Pipeline by Cetya Therapeutics Inc, 2022
- Table 28: Thalassemia – Pipeline by Complexa Inc, 2022
- Table 29: Thalassemia – Pipeline by CRISPR Therapeutics AG, 2022
- Table 30: Thalassemia – Pipeline by CSL Ltd, 2022
- Table 31: Thalassemia – Pipeline by Disc Medicine Inc, 2022
- Table 32: Thalassemia – Pipeline by DisperSol Technologies LLC, 2022
- Table 33: Thalassemia – Pipeline by EdiGene Inc, 2022
- Table 34: Thalassemia – Pipeline by Editas Medicine Inc, 2022
- Table 35: Thalassemia – Pipeline by Epidestiny Inc, 2022
- Table 36: Thalassemia – Pipeline by Forma Therapeutics Inc, 2022
- Table 37: Thalassemia – Pipeline by Fulcrum Therapeutics Inc, 2022
- Table 38: Thalassemia – Pipeline by Gamida Cell Ltd, 2022
- Table 39: Thalassemia – Pipeline by Garuda Therapeutics Inc, 2022
- Table 40: Thalassemia – Pipeline by Gilead Sciences Inc, 2022
- Table 41: Thalassemia – Pipeline by Graphite Bio Inc, 2022
- Table 42: Thalassemia – Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2022
- Table 43: Thalassemia – Pipeline by Imago BioSciences Inc, 2022
- Table 44: Thalassemia – Pipeline by ImmuneCyte Inc, 2022
- Table 45: Thalassemia – Pipeline by Invenux LLC, 2022
- Table 46: Thalassemia – Pipeline by Ionis Pharmaceuticals Inc, 2022
- Table 47: Thalassemia – Pipeline by Jasper Therapeutics Inc, 2022
- Table 48: Thalassemia – Pipeline by Jazz Pharmaceuticals Plc, 2022
- Table 49: Thalassemia – Pipeline by Kanglin Biotech Hangzhou Co Ltd, 2022
- Table 50: Thalassemia – Pipeline by Kymab Ltd, 2022
- Table 51: Thalassemia – Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022
- Table 52: Thalassemia – Pipeline by Merganser Biotech Inc, 2022
- Table 53: Thalassemia – Pipeline by Monte Rosa Therapeutics Inc, 2022
- Table 54: Thalassemia – Pipeline by Nanomedic Inc, 2022
- Table 55: Thalassemia – Pipeline by Orchard Therapeutics Plc, 2022
- Table 56: Thalassemia – Pipeline by Phoenicia Biosciences Inc, 2022
- Table 57: Thalassemia – Pipeline by Rare Partners Srl, 2022
- Table 58: Thalassemia – Pipeline by Regenacy Pharmaceuticals LLC, 2022
- Table 59: Thalassemia – Pipeline by San Rocco Therapeutics LLC, 2022
- Table 60: Thalassemia – Pipeline by Sana Biotechnology Inc, 2022
- Table 61: Thalassemia – Pipeline by Sanquin Plasma Products BV, 2022
- Table 62: Thalassemia – Pipeline by Shanghai Bendao Gene Technology Co Ltd, 2022
- Table 63: Thalassemia – Pipeline by Shanghai Bioray Laboratory Inc, 2022
- Table 64: Thalassemia – Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
- Table 65: Thalassemia – Pipeline by Silence Therapeutics Plc, 2022
- Table 66: Thalassemia – Pipeline by Suzhou GenAssist Therapeutics Co Ltd, 2022
- Table 67: Thalassemia – Pipeline by Syros Pharmaceuticals Inc, 2022
- Table 68: Thalassemia – Pipeline by TransThera Sciences (Nanjing) Inc, 2022
- Table 69: Thalassemia – Pipeline by Vera Therapeutics Inc, 2022
- Table 70: Thalassemia – Pipeline by Vertex Pharmaceuticals Inc, 2022
- Table 71: Thalassemia – Pipeline by Vifor Pharma Ltd, 2022
- Table 72: Thalassemia – Dormant Projects, 2022
- Table 73: Thalassemia – Dormant Projects, 2022 (Contd..1)
- Table 74: Thalassemia – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Thalassemia, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.